 NEWTOWN, Pa., July 14, 2020 GLOBE NEWSWIRE -- Helius Medical Technologies, Inc. NASDAQ:HSDT TSX:HSM Helius or the Company, announced the dismissal of a putative shareholder class action in the Southern District of New York. The plaintiffs voluntarily dismissed the 2019 lawsuit with prejudice, ending the case against Helius in In re Helius Medical Technologies Litigation, 19-CV-6365. U.S. District Judge Loretta Preska signed the final order dismissing the litigation on July 1, 2020.We are gratified that this meritless lawsuit has been dismissed, said Helius CEO and Chairman Philippe Deschamps. We have maintained from the outset that we never misled anyone, and these claims were baseless. I, along with Joyce LaViscount, Jonathan Sackier and the rest of our leadership team, remain fully committed to our mission and protecting the interests of our investors.About Helius Medical Technologies, Inc.Helius Medical Technologies is a neurotech company focused on neurological wellness. The Companys purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brains ability to heal itself. The Companys first product in development is the Portable Neuromodulation Stimulator PoNSTM. For more information, visit the PoNS Device and PoNS TreatmentThe Portable Neuromodulation Stimulator PoNS is an authorized class II, non-implantable medical device authorized for sale in Canada. PoNS is intended as a short term treatment 14 weeks of chronic balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with physical therapy and indicated as a short term treatment 14 weeks of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy. The PoNS is an investigational medical device in the United States, the European Union, and Australia, and is currently under review for clearance by the AUS Therapeutic Goods Administration. PoNS is not commercially available in the United States, the European Union or Australia.Cautionary Disclaimer Statement: Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as believe, continue, look forward, will and similar expressions. Such forward-looking statements include, among others, statements regarding the outcome of pending or future litigation, the Companys future clinical and regulatory development plans for the PoNS, the success of the Companys planned study, business and commercialization initiatives and objectives, the potential receipt of regulatory clearance of the PoNS device in the United States, the European Union and Australia and the Companys revenue guidance.There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Companys expectations include the uncertainties associated with clinical trial enrollments and the results of clinical trials, uncertainties associated with the clinical development process and FDA regulatory submission and approval process, including the Companys capital requirements to achieve its business objectives and other risks detailed from time to time in the filings made by the Company with securities regulators, and including the risks and uncertainties about the Companys business described in the Risk Factors sections of the Companys Annual Report on Form 10-K for the year ended December 31, 2019, and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at or reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.Investor Relations Contact:Westwicke Partners on behalf of Helius Medical Technologies, Inc.Mike Piccinino, 